Nicotine Tob Res. 2022 Apr 13:ntac096. doi: 10.1093/ntr/ntac096. Online ahead of print.
INTRODUCTION: Cannabis use is increasing among cigarette smokers in the United States (US). Prior studies suggest that cannabis use may be a barrier to smoking cessation. Yet, the extent to which this is the case among adults seeking to quit tobacco use remains unclear. Tobacco quitlines are the most common provider of no-cost treatment for adults who use smoke in the US. This study investigated the association of cannabis use with smoking cessation outcomes among Quitline callers.
METHODS: Participants included callers to the New York State Smokers’ Quitline, who were seeking to quit smoking cigarettes and were contacted for outcome assessment 7 months after intake. Thirty-day point prevalence abstinence rates were calculated and compared among cannabis use groups, based on frequency of past-30-day cannabis use at baseline (none: 0 days, occasional: 1-9 days, regular: 10-19 days and daily: 20-30 days.
RESULTS: Approximately 8.3% (n=283) of participants (n=3,396) reported past-30-day cannabis use at baseline. Callers with daily cannabis use (20-30 days per month) had significantly lower odds of 30-day abstinence, relative to those who did not use cannabis (odds ratio=0.5; 95% confidence interval (0.3, 0.9)).
CONCLUSIONS: Daily cannabis use appears to be associated with poorer smoking cessation treatment outcomes among adults seeking to quit smoking cigarettes via a quitline. Because quitlines are among the most accessible, affordable and frequently utilized community-based treatments available in the US, and prevalence of cannabis use is increasing among cigarette smokers, detailed inquiry into cannabis use might enhance knowledge about its impact on smoking cessation.
Source: ncbi 2